Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Sells Shares

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed sales of common stock on September 10, 2024, according to a recent SEC Form 4 filing.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, Inc. (SPRY), reported the sale of company stock on September 10, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan established on March 31, 2023.
• Two transactions were reported, each involving the sale of 50,000 shares of common stock.
• The weighted average sale price for the first transaction was $11.4973, with prices ranging from $11.28 to $11.82.
• The weighted average sale price for the second transaction was $11.4982, also with prices ranging from $11.28 to $11.82.
• Following these transactions, Tanimoto directly owns 3,407,847 shares.
• Tanimoto also has indirect ownership through various trusts, including the Richard Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, the Sarina Tanimoto Charitable Remainder UniTrust, and shares held by her spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment towards the company's future.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. However, large or frequent sales can sometimes be viewed negatively by investors.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they interpret the sales negatively, potentially leading to a slight decrease in stock price.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely to be minimal.

Key Dates